Skip to content
Med Pharma News

Med Pharma News

Your Daily Dose of Pharma News

  • About Med Pharma News
  • Contact Us
  • News
  • Privacy Policy
  • Terms and Conditions
  • Home
  • emestedastat

Tag: emestedastat

Xanamem Alzheimer's trial infographic: XanaMIA CDR-SB result, 247 patients, over-75 subgroup
  • Pharmaceuticals

Xanamem Alzheimer’s Trial Misses Main Goal, Actinogen Shares Plunge Over 80%

Megan Wood1 hour ago010 mins

Actinogen’s oral Xanamem missed its CDR-SB primary endpoint in the 247-patient XanaMIA Alzheimer’s trial. We explain the over-75 subgroup signal, the share collapse and what comes next.

Read More

Categories

  • Healthcare IT (26)
  • Industry Insights (367)
  • Lifestyle and Wellness (24)
  • Medical Devices (45)
  • Pharmaceuticals (113)
  • Uncategorized (1)

Recent Posts

  • Xanamem Alzheimer’s Trial Misses Main Goal, Actinogen Shares Plunge Over 80%
  • AI Drug Discovery Timelines: Big Pharma Says Early Research Now Runs Up to Twice as Fast
  • UnitedHealth Star Ratings Lawsuit: Insurer Sues CMS Over 45 Medicare Advantage Contracts
  • Merck sac-TMT Trial Wins on Survival in Late-Line Gastroesophageal Cancer, Misses on PFS
  • Merck Isomorphic Labs Collaboration: AI Design Deal Targets One Undisclosed Cancer Target
Digital Newspaper - Multipurpose News WordPress Theme 2026. Powered By BlazeThemes.